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ABSTRACT  
Background:  The clinical outcomes following rituximab (RTX) treatment in patients with 
SLE is highly variable. We aimed to identify predictive and prognostic factors associated 
with RTX therapy outcomes in patients with SLE. 
Methods: Studies in adults and paediatric patients with SLE were included. We included 
randomized clinical trials (RCTs) for predictors of differential treatment effect and cohort 
studies for potential prognostic factors in patients treated with RTX (global clinical, 
cutaneous and renal either response or relapse and side effects). Methodological quality was 
assessed using Cochrane Collaboration Risk of Bias tool and the Quality In Prognosis Studies 
Tool (QUIPS) for RCTs and cohort studies, respectively. The quality of subgroup analyses 
testing predictors of differential treatment response was also evaluated. A best evidence 
synthesis was performed using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) framework. 
Results: Sixteen articles were included (3 from 2 RCTs and 13 from 6 cohort studies). The 
overall quality of evidence (QoE) was low to very low (GRADE framework). QoE for 
predictive factors based on RCTs analysing sociodemographic variables, was rated very low 
due lack interaction tests, limited power of subgroup analyses, study limitations and 
imprecisions. Disease-related factors including clinical phenotype and severity, baseline anti-
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ENA antibodies and anti-Ro antibodies, interleukin (IL) 2/21 single nucleotide polymorphism 
(SNP), as well as post-RTX complete B cell depletion and earlier B cell repopulation showed 
some evidence for prognostic value, but were rated low to very low QoE because of early 
phase of investigation (exploratory analysis), insufficient adjustment for confounding in most 
studies, high risk of bias, inconsistency and imprecisions.  
Conclusions: To date studies addressing prognostic factors are hypothesis generating and 
cannot be used to make any specific recommendations for routine clinical practice. A number 
of potential predictors/prognostic factors were identified which require to be validated as 
being specific for response to RTX therapy and to enable more personalised use of this agent. 
 1. INTRODUCTION  
Personalised medicine research is emerging across a number of medical disciplines [1] and if 
successful will enable us to move from “all comer” or “empirical” medicine to a more 
targeted approach thus making the best decisions for individuals or groups of similar patients 
[2;3]. A stratified medicine approach requires testing of patients for the presence of factors 
considered predictive of an improved treatment response (more benefit, less harm, or both) 
compared to other (active) treatment options. Thus, the ability to target optimal therapy to the 
right patient will have an impact on healthcare delivery, quality and costs of care. 
SLE is an autoimmune disease characterized by loss of tolerance to nucleic acids and highly 
diverse clinical manifestations [4]. B cell depletion with the anti-CD20 monoclonal rituximab 
(RTX) has been found to be effective in a number of autoimmune conditions including 
rheumatoid arthritis (RA) [5]. Successful use of RTX in patients with SLE has been reported 
in a number of open-label cohorts studies [6] and a recent meta-analysis supported its 
effectiveness in refractory SLE [7]. Two RCTs of RTX in patients with SLE (EXPLORER 
[8] and LUNAR [9]) did not however achieve their primary end points. Some researchers 
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have cogently argued that various aspects of trial design could account for these apparent 
failures [6]. RTX is therefore now an established drug used in the treatment of SLE and its 
use is supported in several guidelines [10;11].  However, variability in biological and/or 
clinical response to RTX has been reported in a number of studies [12;13]. In addition to 
study design issues, heterogeneity of the SLE population is also likely to contribute to these 
variable results, suggesting a single therapy or therapeutic approach may not be equally 
effective in all patients with SLE. A better understanding of why some patients respond better 
than others to RTX and in particular which factors are associated with better responses (or 
more adverse events) is therefore important to optimize and better target the use of this 
therapy to improve patient outcomes.    
The objectives of this systematic review therefore were: (1) to identify predictors of 
differential response (moderators) to RTX therapy for SLE in RCTs; and (2) to identify 
prognostic factors associated with outcomes following RTX therapy in cohort studies of 
patients with SLE. 
 
2. METHODS 
2.1 Literature search 
Studies were identified through a systematic literature search in the following databases: 
MEDLINE via Ovid (1946 to December 2015), EMBASE via Ovid (1974 to December 
2015), The Cochrane Central Register of Randomized Controlled Trials (CENTRAL-The 
Cochrane Library) via Ovid (to December 2015) and Web of Science (to December 2015) 
Additional studies were identified through a review of the included studies’ reference lists. 
To ensure proper interpretation of the results by our team, publication language was restricted 
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to English, Italian or Spanish.  The search strategies used for Ovid MEDLINE® and applied 
to other databases in the literature are available in Supplementary file A, Table A.1. 
 
2.2 Selection criteria 
Publications were included in the review if they met the following inclusion criteria: (1) 
RCTs and quasi-randomized studies in all different phases that compared RTX therapy versus 
control in SLE patients, (2) Prospective or retrospective cohort studies, which have included 
at the beginning of follow up not less than 30 patients. We decide to include observational 
cohorts with a minimum of 30 patients in our systematic review because, for prognostic 
factors, there are accepted methods for calculating the sample size for binary or continuous 
outcomes [14], and if confounding factors also are considered, smaller sample size would 
have been irrelevant for our purposes. We also excluded review articles, opinion papers, 
letters to the editor, case reports, case series or conference abstracts. RCTs or cohort studies 
reporting outcomes for RTX therapy as a combination therapy with immunosuppressant 
agents (except when RTX was added to previous stable dose treatment) were also excluded. 
 
2.3 Study screening 
References and abstracts identified by the search were imported into Reference Manager 
(RefMan) Version 12 and duplicates were removed. The resulting titles and abstracts were, 
independently, reviewed by CP and CMP. If titles and abstract did not give enough 
information to judge eligibility, full manuscripts were procured and independently reviewed 
by two reviewers (CP and CMP). The full text of each article was then tested against all 
inclusion and exclusion criteria. The review team made every effort to identify multiple 
publications from a single study to obtain all relevant information from trials and cohorts. 
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Disagreements regarding eligibility were resolved through discussion or by a third reviewer 
(INB or BP) if necessary. The bibliographies of all included studies were manually screened 
for additional articles of interest.  
 
2.4 Data extraction 
Standardised data extraction forms were used extract the following study details for RCTs:  
author identification, year of publication, setting, number of patients included, intervention 
and control treatment including dose and administration details, duration of follow-up, 
differential treatment predictors or subgroups analysis and relevant outcomes; and for 
prognostic cohort studies: study design, setting, study duration, number of patients included, 
prognostic factors, relevant outcomes and adjustment for confounders. Definitions for 
prognostic factors or outcomes were taken from the included publications (Supplementary 
file A, Table A.2). Data extraction was done independently by 2 reviewers (CP and CMP). 
When available, estimates of treatment effects for patient subgroups in RCTs, and 
associations of prognosis factors with treatment outcome in cohorts were extracted from each 
published report. Where insufficient information on these estimates was provided in original 
reports, where possible we used available data to calculate relative risks and corresponding 
95% confidence interval (95% CI) using methods recommended in the Cochrane Handbook 
for Systematic Reviews of interventions [15]. Moderators or prognostic factors had to have 
been measured either at baseline or during RTX therapy.  
 
2.5 Methodological quality assessment 
In accordance with PRISMA guidelines we assessed methodological quality of included 
studies [16]. The methods used in this for quality appraisal are described in detail elsewhere 
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[17], but in short, the Cochrane risk of bias tool [18-20] was used for RCTs, while the Quality 
In Prognosis Studies Tool was used to assess risk of bias in cohort studies (Supplementary 
file A, table A.3). The quality of subgroup (moderation) analyses in RCTs was also evaluated 
using criteria proposed by Pincus et al [19]. Two reviewers (CMP and MOS) independently 
rated the methodological quality of the selected studies. The two reviewers discussed 
disagreement about whether a criterion was met, which were resolved by consensus.  
 
2.6 Data synthesis 
Due to the expected heterogeneity of selected studies, we performed a narrative best evidence 
synthesis to summarize evidence for potential predictors from RCTs and prognostic factors 
from cohort studies, which takes into account the strength of the association and the 
methodological quality of the studies. We identified 3 PICO (Population, Intervention, 
Comparator, Outcome) questions [21] regarding potential predictors of the effect of RTX  
and 4 PICO questions regarding prognostic factors to structure the evidence synthesis. The 
overall quality of evidence (QoE) was assessed for each PICO question for RCTs using 
GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) for 
RCTs [22] and the GRADE adaptation for prognostic evidence [23] (Supplementary file A, 
Table A.4).  The PICO comparison (C) category was not applicable and dropped for cohort 
studies. 
We used Review Manager (RevMan) to summarize the data and GRADE profiler 
(GRADEpro) software to produce the GRADE profile [24]. More details about GRADE 
evaluation can be found elsewhere (Supplementary file A, Tables A.5 and A.6) [17]. 
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3. RESULTS 
3.1 Literature search 
The electronic searches resulted in 734 records after exclusion of duplicates, and 94 full 
articles were assessed for eligibility (see PRISMA flow chart, Figure 1). A total of 16 articles 
met the eligibility criteria and were included in the review (3 papers from 2 RCTs and 13 
papers from 6 cohort studies). A list of excluded studies and the reason for exclusion are 
available in Supplementary file A, Table A.7). 
 
3.2 Study characteristics 
The characteristics of the included studies are given in Tables 1 and 2 (RCTs and cohort 
studies respectively). We included analyses from 2 RCTs [8;9], one of which was reported in 
a separate secondary paper with a biomarker endpoint [25].  One RCT reported on multiple 
potential predictors of the effect of RTX [8]. From two RCTs, we extracted data only in the 
RTX arm when specific possible predictors for this therapy were only examined in this 
group; we displayed these results in the tables for prognostic factors used in cohort studies 
[9;25].   
Across RCTs and cohorts five studies included participants aged 15–17 years [8;9;26-28], 
while seven studies only included patients ≥ 18 years [29-33]. In five studies, mean age was 
not reported [13;34-37]. The follow-up duration varied from 24-78 weeks (6-18 months) for 
RCTs and 6-60 months for cohort studies. One RCT (or subgroup analyses) included only 
patients with active LN [9] and one evaluated patients with extra-renal manifestations [8]. 
Two cohort studies took into account active LN [9;28;32], one study evaluated 
mucocutaneous either response or flare [37] and the remaining studies analysed global 
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clinical response or relapse. No cohort studies were identified that described the association 
of sociodemographic factors with outcomes in SLE patients with RTX (PICO 4).  
 
Figure 1 Study flow diagram detailing the literature search 
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Table 1 Characteristics of RCTs evaluating the effectiveness of rituximab in patients with 
SLE   
Study 
ID 
PIC
O 
Setting Populatio
n 
No. 
patient
s 
Interventi
on 
Follo
w-up 
Possible 
Predictor 
Outcomes  
Merri
ll et 
al. [8] 
* 
1     
2     
3  
Internation
al 
Moderatel
y-to-
Severely 
Active 
SLE 
257  Rituximab 
1,000 mg  
(n= 169) or 
placebo 
(n= 88) on 
days 1, 15, 
168, and 
182. 
52 w Age 
Gender 
Race 
Assigned 
prednisone dose 
Background 
immunosuppress
ant 
Duration of lupus 
Baseline BILAG 
A score 
Baseline BILAG-
defined 
mucocutaneous 
or 
musculoskeletal 
system 
involvement 
Major 
clinical 
response  
Partial 
clinical 
response   
Overall 
response  
No response  
Rovin 
et al.  
[9] 
3       Internation
al 
LN III, IV 144       Rituximab 
1 g on d 1, 
15, 168, 
182 + 
MMF 3 g/d 
(n= 72) or 
MMF (3 
g/d) (n= 
72) 
52 w        
78 w 
B cells at 
baseline  
Overall 
response 
B cells depletion 
Tew 
et al. 
[25]* 
3 Internation
al 
Moderatel
y-to-
Severely 
Active 
SLE 
257 Rituximab 
1,000 mg 
(n=169) or 
placebo 
(n= 88) on 
days 1, 15, 
168, and 
182 
52 w 
Autoantibodies 
B cells levels 
Interferon 
signature 
Normalizati
on of 
complement 
and anti-
dsDNA 
 
Studies are listed in alphabetical order. * multiple papers on partially the same trial cohort  HACA, human 
antichimeric antibody; IVC, intravenous cyclophosphamide; LN, lupus nephritis; MMF,  mycophenolate 
mofetil;  PICO, Population, Intervention, Comparator, Outcome (number of PICO question);  RCT, randomized 
clinical trial; w, weeks. 
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Table 2 Characteristics of studies on prognostic factors 
Study 
ID 
Setting PIC
O 
Design No. 
patie
nts 
Dose of 
rituxim
ab 
Follo
w-up 
Possible 
Predictor 
Outcomes  Adjustment 
for 
confounders 
Carter 
et al. 
[26] ¥ 
UK 7 Retrospe
ctive 
cohort 
35 1 g x 2 
plus 750 
mg IVC 
66 
w‡ 
Serum 
BAFF 
levels  
Clinical 
Relapse  
Not indicated 
Changes 
in B cells 
High anti-
dsDNA 
Catapa
no et 
al. [29] 
UK 7 Retrospe
ctive 
cohort 
31 375 
mg/m2/
week × 
4 or 
1000 mg 
× 2 
30  
m‡ 
Serologic 
features 
Response Not indicated 
Relapse 
Dias et 
al.  [30] 
¥ 
UK 7 Retrospe
ctive 
cohort 
98 1 g x 2 
plus 750 
mg IVC 
5 y† Longer 
duration of 
BCD 
Clinical 
improvem
ent 
Sociodemogr
aphic, 
clinical and 
serological 
features 
Fernan
dez-
Nebro 
et al. 
[31]  
Spain 6  Retrospe
ctive 
cohort 
116 375 
mg/m
2
/w
eek × 4 
or 1000 
mg × 2 
20 
m† 
Disease 
related 
variables 
Clinical 
response 
Sociodemogr
aphic, 
clinical and 
treatment 
variables 
Adverse 
events 
Jónsdót
tir et al.  
[32] *¥ 
Internati
onal 
6 Retrospe
ctive 
cohort 
43 375 
mg/m2/
week × 
4 or 
1000 mg 
× 2 plus 
500-
1000 mg 
IVC  
6 m LN 
histopathol
ogical class 
Renal 
improvem
ent 
Not indicated 
Lazaru
s et al. 
[27] ¥ 
UK 7 Retrospe
ctive 
cohort  
61 1 g of 
rituxima
b x 2 
plus 750 
mg IVC  
52 w Anti-
dsDNA 
antibody 
levels at 
baseline 
B cell 
repopulatio
n 
Clinical 
relapse 
 
Not indicated 
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Lindho
lm et 
al. [28] 
Sweden 6      
7 
Retrospe
ctive 
cohort 
33 375 
mg/m²/w 
x 4 w 
22 
m‡ 
LN 
duration  
Baseline 
serum 
creatinine 
Baseline 
proteinuria 
Baseline 
Anti-
dsDNA 
Baseline 
detectable 
B cell 
Renal 
response 
Not indicated 
Marque
z et al. 
[36]# 
Spain 5 Prospecti
ve cohort 
84 375 
mg/m2/
week × 
4 or 
1000 mg 
× 2 
6 m Genetic 
factors 
Clinical 
Complete 
response 
Socio-
demographic 
and 
concomitant 
therapies 
 
Ng et 
al. [33] 
¥ 
UK 7 Retrospe
ctive 
cohort 
32 1 g of 
rituxima
b x 2 
plus 
500-750 
mg IVC 
 
39 
m‡ 
Anti-ENA Clinical 
flare 
Performed 
but unknown 
confounders 
Robled
o et al. 
[34] # 
Spain 5 Prospecti
ve cohort 
81 375 
mg/m
2
/w
eek × 4 
or 1000 
mg × 2 
6 m Genetic 
factors 
Clinical 
response 
Not indicated 
Robled
o et al 
[35] # 
Spain 5 Prospecti
ve cohort 
83 375 
mg/m
2
/w
eek × 4 
or 1000 
mg × 2 
6 m Genetic 
factors 
Clinical 
response 
Not indicated 
Vital et 
al. [13] 
& 
UK 7 Prospecti
ve cohort 
39 1000 mg 
× 2 
6 m Anti-ENA 
B cell 
depletion 
B cell 
repopulatio
n 
Clinical 
response 
Not indicated 
Clinical 
relapse 
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Vital et 
al. [37] 
& 
UK 6        
 7 
Retrospe
ctive 
cohort 
82 1000 mg 
× 2 
6 m Cutaneous 
phenotype 
Autoantibo
dies 
Compleme
nt 
B cell 
depletion 
Mucocuta
neous 
response 
Cutaneous 
flare 
Not indicated 
 
Studies are listed in alphabetical order; †mean, ‡median; ¥, # and & multiple papers on partially the same 
cohort.  Anti-ENA: anti-extractable nuclear antigen; BAFF, B-cell–activating factor; HCQ: 
hydroxychloroquine; m, months; IVC, intravenous cyclophosphamide; LN, lupus nephritis; MLN, membranous 
lupus nephritis;  PICO, Population, Intervention, Comparator, Outcome (number of PICO question); RCT, 
randomized clinical trial; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National 
Assessment-SLE disease activity index; UK, United Kingdom;  w, weeks; y, years 
 
 
3.3 Characteristics of possible predictive or prognostic factors and outcomes to RTX 
Predictive or prognostic factors were grouped into six categories: sociodemographic, genetic, 
disease related, and laboratory biomarkers. Outcomes were evaluated as follows:  global, 
renal or cutaneous response/remission were evaluated by 12 studies [8;9;13;27;28;30-32;34-
37]; global, renal or cutaneous relapse/flare were reported in 5 studies [26;27;29;33;37]; 
harms including adverse events were evaluated by 2 studies [13;31] and changes in 
biomarkers were reported in 4 studies [9;13;25;26].  
 
3.4 Methodological quality of included studies 
3.4.1 Risk of bias in RCTs 
Risk of bias assessment was based on the main results paper of the included RCTs. The 
methods of randomisation and allocation concealment were unclear (high risk) in both RCTs. 
Two trials were described as double blinded (participant and outcome assessment) and rated 
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as low risk of performance and detection bias [8;9]. These trials included an intention to treat 
(ITT) analysis, had no evidence of selective outcome reporting and dropout rate analyses 
were adequately presented (low risk of attrition bias). The RCTs either declared sponsorship 
by a pharmaceutical industry company, or included an author who declared pharmaceutical 
company affiliation; these were judge as carrying high risk bias related to the funding source 
(Figure 2). 
Figure 2 Risk of bias summary of RCTs included 
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3.4.2 Quality of subgroups (moderation) analysis 
At least nine subgroup analyses were conducted in one RCT [8], without providing a clear 
rationale a priori for most of them. None of the sub-group analyses provided confirmatory 
evidence with one analysis providing exploratory evidence only (Supplementary file B, Table 
B.1).  
 
3.4.3 Risk of bias in prognostic factor studies based on observational cohorts 
The overall methodological quality of six studies scored ‘moderate’, seven studies scored 
‘low’, and no study was judged as ‘high’ quality (Supplementary file B, Table B.2). Due to 
lack of reporting on key characteristics of the source population (‘study participation’) and of 
participants loss to follow-up (‘study attrition’), bias could not be ruled out, therefore studies 
were classified as ‘moderate’ (n = 4) or ‘high’ risk (n = 9) of selection bias. In 10 studies, 
measurement of prognostic factors and outcomes were performed in a similar, valid, and 
reliable way for all participants (‘low’ to ‘moderate’ risk of bias), although, in three studies 
outcomes measurements were based on clinical judgment instead of valid criteria [34-36], 
resulting in high risk of bias for these domains The statistical analysis, model-building 
process or completeness of reporting was judged to be inadequate in all studies (‘moderate’ to 
‘high’ risk of bias). In particular, there was insufficient description of how factors were 
selected for inclusion in the multivariable analysis (Supplementary file D, Table D.1-D.7).  
3.5 Synthesis of evidence 
3.5.1 Sociodemographic factors (PICO 1 and 4) 
3.5.1.1 Age, gender and race  
One RCT [8] found no association between age or gender and response to RTX. In a pre-
specified secondary analysis being of African American/Hispanic race/ethnicity showed a 
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larger effect of RTX on no clinical response at week 52 compared to those of other ethnic 
origin. No differences were seen for secondary endpoints such as quality of life or major 
clinical response with a prednisone dosage of < 10 mg/day in the same subgroup (low QoE, 
Supplementary file C).  
3.5.2 Genetic factors (PICO 5) 
In one cohort study [36], both IL2/IL21 (rs6822844) GG genotype and G allele were 
significantly associated with clinical response when adjusted for age, gender and concomitant 
therapies (OR = 6.43 95% CI 1.42–21.07) (Table 3). The QoE for this association was 
downgraded to low due to the early phase of investigation designed to generate hypotheses 
and imprecision of the results but also upgraded given the strength of the association 
(Supplementary file D, Table D.1).  
Two other genetic variants -174 IL6 (rs1800795) and Fc gamma-receptor III a (FCGR3A) 
158F/V were evaluated in a single cohort study each and were not related to clinical response 
[34;35] (Table 3).   
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Table 3 Summary of evidence for factors associated with global clinical response 
 
 
Factor identified Study N Outcom
e 
Unadjusted 
ES (95% 
CI)/univaria
ble analysis 
P 
valu
e 
Adjust
ed ES 
(95% 
CI) 
P 
value 
Overa
ll 
qualit
y 
G
en
et
ic
 
- 174 IL-6 
(rs1800795) 
SNP GG vs 
GC genotype 
Robledo 
et al. 
[34] 
40/3
6 
Complet
e or 
partial 
response 
36 (90.0%) 
vs 32 
(88.9%) 
RR=1.01  
(0.87-1.18) 
0.87 NP NP  
- 174 IL-6 
(rs1800795) 
SNP GG vs 
CC genotype 
Robledo 
et al. 
[34] 
40/8 Complet
e or 
partial 
response 
36 (90.0%) 
vs 5 (62.5%) 
RR=1.26  
(0.77-2.03) 
0.34 NP NP  
- 174 IL-6 
(rs1800795) 
SNP GC vs 
CC genotype 
Robledo 
et al. 
[34] 
36/8 Complet
e or 
partial 
response 
32 (88.9%) 
vs 5 (62.5%) 
RR=1.42  
(0.82-2.46) 
0.21 NP NP  
FCGR3A-158 
SNP VV vs 
FF genotype  
Robledo 
et al. 
[35] 
13/4
4 
Complet
e or 
partial 
response 
12 (92.3%) 
vs 36 
(81.8%)  
RR=1.13 
(0.91-1.39) 
0.25 NP NP  
FCGR3A-158 
SNP FV vs 
VV genotype  
Robledo 
et al. 
[35] 
24/1
3 
Complet
e or 
partial 
response 
23 (95.8%) 
vs 12 
(92.3%) 
RR=1.04 
(0.87 to 
1.24) 
0.68 NP NP  
FCGR3A-158 
SNP FV vs FF 
genotype  
Robledo 
et al. 
[35] 
24/4
4 
Complet
e or 
partial 
response 
23 (95.8%) 
vs 36 
(81.8%) 
RR=1.17 
(0.99-1.37) 
0.05
6 
NP NP  
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IL2/IL21 SNP 
(rs6822844) 
GG vs GT 
genotype  
Marquez 
et al. 
[36] 
66/1
8 
Complet
e or 
partial 
response 
61 (92.4%) 
vs 12 
(66.7%); RR 
= 1.39 
(0.99–1.94) 
0.05
5 
OR = 
6.43 
(1.42–
21.07) 
0.016  
D
is
ea
se
-r
el
at
ed
 
Baseline 
SLEDAI 
Fernande
z-Nebro 
et al. 
[31] 
116 
Complet
e/ 
partial 
remissio
n 
OR= 1.1 
(1.03-1.2) 
 
0.00
1 
OR= 
1.1, 
(1.04-
1.16) 
0.001  
Previous 
discoid rash  
Fernande
z-Nebro 
et al. 
[31] 
116 
Complet
e or 
partial 
remissio
n 
OR= 4.4  
(1.2-15.8) 
0.02
5 
NS 0.08  
Previous 
severe 
hematologic 
disorder 
Fernande
z-Nebro 
et al. 
[31] 
116 
Complet
e or 
partial 
remissio
n 
OR= 0.3 
(0.1-0.7) 
0.00
3 
OR= 
0.17 
(0.06-
0.46) 
<0.00
1 
 
Previous 
treatment with 
immunoglobul
ins 
Fernande
z-Nebro 
et al. 
[31] 
113 
Complet
e or 
partial 
remissio
n 
OR= 0.3 
(0.3-0.7) 
0.00
7 
NS 0.13  
Previous 
treatment with 
prednisolone 
≥ 100 mg/day 
Fernande
z-Nebro 
et al. 
[31] 
116 
Complet
e or 
partial 
remissio
n 
OR= 1.3 
(1.1-15.0) 
0.03
2 
OR= 
7.3    
(1.6-
32.9) 
0.010  
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
 
BCD   <12 vs 
≥ 12 months 
Dias et 
al. [30] 
34/6
4 
BILAG 
score at 
6 
months 
8.78 vs 5.89 0.00
4 
NP NP  
BILAG 
score at 
12 
months 
7.64 vs 5.29 0.01
7 
NP NP  
 20 
Complete vs. 
incomplete 
BCD  
Vital et 
al. [13] 
16/2
1 
Major 
or 
partial 
clinical 
response 
16 (100%) 
vs 14 
(66.7%) 
RR = 1.5 
(1.10-2.02) 
0.00
8 
NP NP  
Abbreviation: BCD: B cells depletion; ES: effect size; CI: confidence interval; NP, 
information not presented, NS: not significant; RR: relative risk; SLEDAI: systemic lupus 
erythematosus disease activity. 
For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high
3.5.3 Disease-related factors (PICO 2 and 6) 
3.5.3.1 Disease phenotype 
BILAG-defined mucocutaneous or musculoskeletal system involvement, were also assessed 
as pre-specified subgroups analysis in the EXPLORER trial with no difference in effect 
estimates found between both interventions groups [8]. The QoE of this RCT was 
downgraded due to these being subgroup analyses with no tests for interaction and providing 
exploratory evidence only.  
 
Similarly, the prognostic value of skin phenotype on response and future flare in two cohort 
studies was unclear with both assessed as having high risk of bias [31;37] (Table 3, 5 and 6). 
In a single cohort study, those with previous serious haematologic disorder were 83% less 
likely to achieve a beneficial response [31] (very low QoE). 
A single (very low QoE) cohort study also found that membranous and proliferative LN had 
similar renal responses following B-cell depleting (BCD) therapy [32] (Table 7).  
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3.5.3.2 Disease severity  
A single RCT found that baseline BILAG A score did not predict a differential clinical 
response to RTX compared to control at week 52 [8]. In contrast, high baseline SLEDAI 
score was associated with better RTX global response at 6 months in one cohort study with 
high risk of bias [31] (Table 3).  
 
A longer duration (median 19 months) of lupus nephritis (LN) was associated with a lower 
likelihood of renal response in one cohort with serious limitations [28]. The age adjusted 
Charlson comorbidity index and the number of severely affected organ systems were 
associated with more severe adverse events and more severe infections with RTX therapy in 
one cohort study (very low QoE) (Table 8) [31].
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Table 4 Summary of evidence for factors associated with overall clinical relapse or flare 
  
 
Factor identified Study N Outcom
e 
Unadjusted 
ES (95% 
CI)/univariabl
e analysis 
P 
valu
e 
Adjuste
d ES 
(95% 
CI) 
P 
valu
e 
Overal
l 
quality 
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
s 
Baseline 
high (>100 
IU/ml) vs 
low or 
normal anti-
dsDNA 
antibodies 
Lazarus 
et al. 
[27] 
26/3
5 
Early 
relapse 
NP NS NP NP  
Baseline 
presence vs 
absence of 
anti-dsDNA 
Catapan
o et al. 
[29] 
14/1
7 
Time of 
relapse 
NP NS NP NP  
Baseline 
presence of 
anti-ENA 
antibodies 
vs lack of 
anti-ENA 
Ng et al. 
[33] 
21/7 
Flare NP 
0.00
7 
OR = 
8.0 
(1.2-55)                                                          
0.03
4 
 
Vital et 
al. [13] 
39 
Early 
relapse 
NP 
Sig NP NP  
Catapan
o et al. 
[29] 
10/2
1 
Time of 
relapse 
NP 
NS NP NP  
Baseline 
BAFF 
levels 
Carter et 
al. [26] 
35 
Relapse NP 
>0.5
5 
NP NP  
B cell 
repopulatio
n: higher 
number of 
memory 
cell 
Vital et 
al. [13]  
32 
Early 
relapse 
NP 
0.02 NP NP  
B cell 
repopulatio
n: number 
of 
plasmablast 
cell 
Vital et 
al. [13] 
32 
Early 
relapse 
80% vs 0% 
< 
0.00
1 
NP NP  
Late 
relapse 
100% vs 27% 
NP NP NP  
 23 
>0.0008 x 
10
9
/liter vs 
<0.0008 x 
109/liter 
B cell 
repopulatio
n with 
higher 
(>100 
IU/ml) vs 
lower anti-
DNA 
antibodies 
levels  
Lazarus 
et al. 
[27] 
17/2
0 
Early 
relapse  
NP 0.02 NP NP  
Abbreviations: anti-ENA: anti-extractable nuclear antigen; BAFF: B-cell–activating factor; 
BCD: B cell depletion; ES: effect size; CI: confidence interval; NP, information not 
presented, NS: not significant; OR: odds ratio; Sig: significant. 
       For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high 
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Table 5 Summary of evidence for factors associated with cutaneous response 
 
 
Factor identified Stud
y 
N Cutaneou
s 
Outcome 
Unadjusted 
ES (95% 
CI)/univariab
le analysis 
P 
valu
e 
Adjuste
d ES 
(95% 
CI) 
P 
valu
e 
Overal
l 
qualit
y 
D
is
ea
se
 r
el
at
ed
 Subtype 
skin 
disease: 
ACLE vs 
CCLE  
Vital 
et al. 
[37] 
14/8 
Response 6 (42.9%) vs 
0 (0.0%) 
RR = 7.8 
(0.49-122.65)  
0.14 NP NP  
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
  
  
Baseline 
positive 
vs. 
negative 
anti-
Ro/SSA 
antibodie
s 
Vital 
et al. 
[37] 
16/1
0 
Response 3 (18.8%) vs 
6 (60.0%) 
RR = 0.31 
(0.10- 0.97) 
0.04 NP NP  
Baseline 
positive 
vs 
negative 
anti-
La/SSB 
antibodie
s 
Vital 
et al. 
[37] 
8/18 
Response 2 (25.0%) vs 
7 (38.9%) 
RR = 0.64 
(0.17-2.43) 
0.65 NP NP  
Baseline 
positive 
vs 
negative 
anti-
dsDNA 
antibodie
s 
Vital 
et al. 
[37] 
14/8 
Response 7 (50.0%) vs 
2 (16.7%) 
RR = 3.0 
(0.82-5.17) 
0.11 NP NP  
Baseline 
positive 
vs 
negative 
anti-Sm 
antibodie
Vital 
et al. 
[37] 
4/22 
Response 1 (25.0%) vs 
8 (36.4%) 
RR = 0.68 
(0.62-2.17) 
0.68 NP NP  
 25 
s 
Baseline 
positive 
vs 
negative 
anti-RNP 
antibodie
s  
Vital 
et al. 
[37] 
7/19 
Response 0 (0.0%) vs 7 
(47.4%) 
RR = 0.13 
(0.008-2.0) 
0.14 NP NP  
Low vs 
normal 
C3 
Vital 
et al. 
[37] 
9/17 
Response 3 (33.3%) vs 
6 (35.3%) 
RR = 0.94 
(0.30-2.91) 
0.09 NP NP  
Low vs 
normal 
C4 
Vital 
et al. 
[37] 
11/1
6 
Response 4 (36.4%) vs 
5 (31.3%) 
RR = 1.16 
(0.40-3.38) 
0.78 NP NP  
Complete  
(0.0001 x 
10
9
 
cells/liter) 
vs 
incomplet
e BCD  
Vital 
et al. 
[37] 
10/1
6 
Response 4 (40.0%) vs 
5 (31.3%) 
RR = 1.28 
(0.44-3.66) 
0.64 NP NP  
ACLE: acute cutaneous lupus erythematosus; BCD: B cells depletion; CCLE: chronic 
cutaneous lupus erythematosus; ES: effect size; NP, information not presented, NS: not 
significant; SCLE: subacute cutaneous lupus erythematosus; SLEDAI: systemic lupus 
erythematosus disease activity. 
For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high 
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Table 6 Summary of evidence for factors associated with cutaneous relapses 
 
Factor identified Study N Cutaneous 
Outcome 
Unadjusted 
ES (95% 
CI)/      
univariable 
analysis 
P 
value 
Adjusted 
ES (95% 
CI) 
P     
value 
Overall 
quality 
D
is
ea
se
 r
el
at
ed
 Subtype 
skin 
disease: 
ACLE vs 
CCLE  
Vital 
et al. 
[37] 
14/8 
Relapse 6 (42.9%) vs 
0 (0.0%) 
RR = 7.8 
(0.49-122.65)  
0.14 NP NP  
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
  
Baseline 
anti-
Ro/SSA 
antibodies 
positive vs 
negative 
Vital 
et al. 
[37] 
17/15 
Relapse 8 (47.1%) vs 
5 (33.3%) 
RR = 1.41 
(0.58 to 3.38) 
0.44 NP NP  
Baseline 
positive vs 
negative 
anti-
La/SSB 
antibodies 
Vital 
et al. 
[37] 
9/23 
Relapse 4 (44.4%) vs 
8 (34.8%) 
RR = 1.28 
(0.51 to 3.20) 
0.60 NP NP  
Baseline 
positive vs 
negative 
anti-
dsDNA 
antibodies 
Vital 
et al. 
[37] 
17/15 
Relapse 7 (41.2%) vs 
5 (33.3%) 
RR = 1.24 
(0.49 to 3.08) 
0.65 NP NP  
Baseline 
positive vs 
negative 
anti-Sm 
antibodies 
Vital 
et al. 
[37] 
4/28 
Relapse 0 (0.0%) vs 
12 (42.9%) 
RR = 0.23 
(0.01-3.32) 
1.07 NP NP  
Baseline 
positive vs 
negative 
anti-RNP 
antibodies  
Vital 
et al. 
[37] 
7/25 
Relapse 4 (57.1%) vs 
8 (32.0%) 
RR = 1.78 
(0.75- 4.21) 
0.18 NP NP  
 27 
Low vs 
normal C3 
Vital 
et al. 
[37] 
12/20 
Relapse 6 (50.0%) vs 
6 (30.0%) 
RR = 1.66 
(0.69-4.00) 
0.25 NP NP  
Low vs 
normal C4 
Vital 
et al. 
[37] 
14/18 
Relapse 6 (42.9%) vs 
6 (33.3%) 
RR = 1.29 
(0.53-3.13) 
 
0.58 NP NP  
Complete 
(0.0001 x 
10
9
) 
cells/liter 
vs 
incomplete 
BCD  
Vital 
et al. 
[37] 
12/20 
Relapse 3 (25.0%) vs 
9 (45.0%) 
RR = 0.56 
(0.19-1.66) 
0.29 NP NP  
ACLE: acute cutaneous lupus erythematosus; BCD: B cells depletion; CCLE: chronic 
cutaneous lupus erythematosus; ES: effect size; NP, information not presented, NS: not 
significant; SCLE: subacute cutaneous lupus erythematosus; SLEDAI: systemic lupus 
erythematosus disease activity. 
       For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high 
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Table 7 Summary of evidence for factors associated with renal response 
 
 
Factor identified Study N Renal 
Outcome 
Unadjusted 
ES (95% 
CI)/univaria
ble analysis 
P 
valu
e 
Adjust
ed ES 
(95% 
CI) 
P 
valu
e 
Overa
ll 
qualit
y 
D
is
ea
se
 r
el
at
ed
 
Duration 
of lupus 
nephritis, 
months 
Lindhol
m et al. 
[28] 
11/6 
Complete/part
ial response 
vs. no 
response 
9 vs 19 NS NP NP  
MLN 
class vs 
PLN class 
Jónsdott
ir et al. 
[32] 
15/2
8 
Increase 
serum 
albumin  
NP NS NP NP  
Mean serum 
creatinine 
levels 
improved 
Only in 
MLN 
NP NP NP  
Reduction in 
proteinuria  
NP NS NP NP  
Improvement 
in C3  
NP NS NP NP  
Reduction in 
anti-dsDNA 
Only in PLN <0.0
2 
NP NP  
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
  
Baseline 
serum 
creatinine, 
μmoles/l 
Lindhol
m et al. 
[28] 
11/6 
Complete/part
ial response 
vs. no 
response 
86.1 ± 30.9 
vs 207.2 ± 
86.6 
0.00
6 
NP NP  
Baseline 
eGFR ≥ 
30 vs < 30 
ml/min 
Lindhol
m et al. 
[28]
 
13/4 
Complete/part
ial response  
11 (84.6%) 
vs 0 (0.0%) 
RR = 8.21 
(0.58 -
115.21) 
0.58 NP NP  
Baseline 
proteinuri
a, g/24 h 
Lindhol
m et al. 
[28] 
11/6 
Complete/part
ial response 
vs. no 
response 
3.4 ± 2.1 vs 
5.0 ± 1.6 
NS NP NP  
Baseline 
anti-
Lindhol 11/6 
Complete/part
ial response 
38 ± 4.9 vs NS NP NP  
 29 
dsDNA 
antibodies
, U/ml 
m et al. 
[28] 
vs. no 
response 
37.5 ± 8.0 
Baseline 
compleme
nt C3, g/l 
Lindhol
m et al. 
[28] 
11/6 
Complete/part
ial response 
vs. no 
response 
1.0  0.1 vs 
1.1  0.3 
NS NP NP  
 Baseline 
detectable 
CD 19+ 
lymphocy
te 
Lindhol
m et al. 
[28] 
11/6 
Complete/part
ial response 
vs. no 
response 
9 (81.8%) vs 
2 (33.3%) 
RR = 2.45 
(0.76-7.87) 
NS NP NP  
BCD: B cells depletion; CCLE: chronic cutaneous lupus erythematosus; eGFR: estimated 
glomerular filtration rate; ES: effect size; HCQ: hydroxychloroquine; MLN: membranous 
lupus nephritis; NP:  information not presented, NS: not significant; PLN: proliferative lupus 
nephritis. 
       For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high 
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Table 8 Summary of evidence for factors associated with side effects 
 
 
Factor identified Study N Overall 
Outcome 
Unadjusted 
ES (95% 
CI)/univaria
ble analysis 
P 
value 
Adjuste
d ES 
(95% 
CI) 
P 
valu
e 
Overa
ll 
qualit
y 
D
is
ea
se
-r
el
at
ed
 
Comorbidit
y* 
Fernande
z-Nebro 
et al. [31] 
125 
Adverse 
events 
HR = 1.6 
(1.1–2.4)  
0.030 HR  = 
1.6 
(1.0–
2.6) 
0.04
9 
 
No. of 
severely 
involved 
organ 
systems 
(per organ 
involved) 
Fernande
z-Nebro 
et al.[31] 
125 Adverse 
events 
HR = 2.0 
(1.4–2.9)  
<0.00
1 
HR = 
2.0 
(1.3–
2.9) 
0.00
1 
 
Previous 
treatment 
with steroid 
bolus 
(Yes/No)  
Fernande
z-Nebro 
et al. [31] 
125 
Adverse 
events 
HR = 5.4 
(2.0–14.8)  
0.001 HR = 
5.9 
(1.9–
18.4) 
0.00
2 
 
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
  
Baseline 
high 
leukocyte 
count, 
x10
9
/L  
Fernande
z-Nebro 
et al. [31] 
125 
Adverse 
events 
HR = 1.2 
(1.0–1.3)  
0.045 HR = 
1.2 
(1.0–
1.4) 
0.04
6 
 
Complete 
BCD 
depletion vs 
incomplete 
BCD cell 
depletion 
Vital et 
al. [13] 
16/2
1 
Hospital 
admissio
ns 
4 (25%) vs 
10 (47.6%) 
RR = 0.54 
(0.20-1.37) 
NP NP NP  
ES: effect size; HR: hazard ratio; NP, information not presented, NS: not significant; 
SLEDAI: systemic lupus erythematosus disease activity; TC: total cholesterol; TGs: 
triglycerides. *Age-adjusted Charlson comorbidity index 
       For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high
The role of previous treatments, a potential proxy of more severe disease or a different 
phenotype, has been evaluated in only two studies (one RCT and one cohort study). In the 
 31 
EXPLORER trial a post-hoc analysis of patients in previous treatment with methotrexate 
found a greater fall in mean BILAG global scores in RTX vs placebo treated patients. There 
was however no difference in achievement of the primary endpoint (low QoE) [8]. Previous 
treatment with prednisone > 100 mg/day was related to better clinical response (very low 
QoE) and previous treatment with steroid bolus was associated with more adverse events 
(low QoE) in one cohort study. It was unclear what other factors were adjusted for in this 
cohort [31].  A univariable analysis in the same cohort also showed that previous treatment 
with immunoglobulins was associated with a reduced likelihood of clinical response; an 
association not confirmed in a multivariate analysis [31] (Table 3).   
 
3.5.4 Laboratory biomarker values (PICO 3 and 7) 
3.5.4.1 Baseline laboratory biomarkers  
In a post-hoc subgroup analysis from the EXPLORER Trial that used normalisation of 
serology as an end-point, patients with positive dsDNA (> 30 UI/ml) who lacked RNA-
binding protein (RBP-) had reduced anti-dsDNA antibodies after RTX treatment compared to 
placebo-treated patients. In contrast, patients with both dsDNA and RBP (> 120 AU/ml) 
antibodies had a similar reduction in anti-dsDNA antibodies in both treatment arms [25]. This 
study also found that repopulation of CD19+ B cells in dsDNA+RBP+ and dsDNA+RBP– 
patients were similar despite differences in anti-dsDNA antibodies levels (Table 9). The QoE 
of this RCT was downgraded due to unclear allocation concealment and post hoc subgroup 
analysis with insufficient evidence. 
Patients with baseline renal impairment (high serum creatinine levels and a GFR < 30 
ml/min) were less likely to have a renal response whilst a higher baseline proteinuria was not 
associated with renal responses in one cohort study. Analyses were not adjusted for potential 
 32 
confounding [28] (Table 7). Baseline high leukocyte count was found to be related to an 
increased risk of severe infections during RTX in one cohort study [31] (very low QoE) 
(Table 8). 
A number of studies assessed baseline levels of biomarkers including anti-double stranded 
DNA (anti-dsDNA) antibodies, low C3 and/or C4 complement, serum B-cell-activating 
factor (BAFF) and baseline CD19 counts. These studies were rated as low QoE and did not 
find any of these to be predictors of treatment outcome. Whilst 4 cohort studies assessed anti-
DNA against a range of global and organ specific response measures, these other baseline 
biomarkers have only been assessed in one or two studies each. 
Univariable analysis from two cohorts [33] found an association between anti-extractable 
nuclear antigen antibody (anti-ENA) and flares, but another cohort failed to find this 
association and only one study confirmed this in a multivariable analysis [33]. Evidence from 
these studies was downgraded because of inconsistency and high risk of bias. 
Regarding specific anti-ENA antibody specificities, anti-Ro was associated with poorer 
mucocutaneous responses but not with mucocutaneous flares in univariable analysis from one 
small cohort [37] (n = 26) very low QoE) (Table 5 and 6). 
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Table 9 Summary of evidence for factors associated with changes in biomarkers 
 
 
Factor identified Stud
y 
N Overall 
Outcome 
Unadjusted 
ES (95% 
CI)/univariab
le analysis 
P 
value 
Adjuste
d ES 
(95% 
CI) 
P 
valu
e 
Overa
ll 
qualit
y 
L
ab
o
ra
to
ry
 b
io
m
ar
k
er
 v
al
u
es
 
Baseline 
high anti-
dsDNA  
(>123/ml) 
Rovi
n et 
al. 
[9] 
72 B cell 
depletion 
NP Sig NP NP  
Baseline 
anti-dsDNA 
titers 
Vital 
et al. 
[13] 
37 Incomplete 
B cell 
depletion 
NP NS NP NP  
Baseline 
anti-
dsDNA
+
RN
P
- 
vs anti-
dsDNA+RN
P
+
 
Tew 
et al. 
[25] 
97/6
8 
Decreased 
anti-
dsDNA 
NP <0.02
5 
NP NP  
Increased 
compleme
nt 
NP NS NP NP  
Baseline 
anti-ENA 
presence 
Vita 
et al. 
[13] 
37 
Incomplete 
B cell 
depletion 
NP NS NP NP  
Baseline low 
C3 or C4 
levels 
Vital 
et al. 
[13] 
37 Incomplete 
B cell 
depletion 
NP NS NP NP  
Baseline 
median 
levels of 
memory, 
cells/liter 
Vital 
et al.  
[13] 
37 
Complete 
depletion 
vs. 
persistent 
B cells 
0.0065 x 10
9
 
vs 0.0157 x 
10
9
 
0.049 NP NP  
Baseline 
median 
levels of 
plasmablast, 
cells/liter 
Vital 
et al. 
[13] 
37 
Complete 
depletion 
vs. 
persistent 
B cells 
0.0015 x 10
9
 
vs 0.0037 x 
10
9
 
0.030 NP NP  
Baseline 
high vs low  
Tew 
et al. 
16/9 
Changes in 
anti-
NP Sig NP NP  
 34 
BAFF [25] dsDNA 
and 
compleme
nt 
Baseline 
BAFF levels, 
ng/ml 
Carte
r et 
al. 
[26] 
34 
Time to 
peripheral 
B cell 
repopulati
on  26 
weeks vs  
26 weeks 
1.12  0.20 
vs 1.52  
0.38  
 
0.05 
NP NP  
Baseline 
positive vs 
negative IFN 
signature  
Tew 
et al. 
[25] 
16/9 
Changes in 
anti-
dsDNA 
and 
compleme
nt 
NP 
NS NP NP  
BAFF: ES: effect size; HR: hazard ratio; NP, information not presented, NS: not significant; 
Sig: significant; SLEDAI: systemic lupus erythematosus disease activity; TC: total 
cholesterol; TGs: triglycerides.  
       For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high 
3.5.4.2 Pharmacodynamic biomarkers post-RTX 
Two cohorts assessed the association between degree of BCD and clinical response (one on 
global response and one for mucocutaneous response). One cohort study (n = 37) found that 
all patients with complete B cell depletion at 6 weeks (n= 16) had higher major or partial 
global clinical responses at 26 weeks, and all non-responders had persistent B cells after RTX 
therapy (n=14) [13]. No association between the degree of initial B cell depletion and 
response was observed for cutaneous disease (n = 26) [37] (Tables 3 and 4), and no 
association was found when using relapse as the outcome in this subgroup.  
One cohort study examined whether BCD could have a relationship with harm during RTX 
therapy (rates of hospitalization). There was no adverse influence on safety in patients with 
complete BCD or prolonged suppression of memory and plasma cell numbers [13] (Table 8).   
 35 
The duration of BCD was evaluated in one cohort study (n = 98), with longer duration (≥ 12 
months) of depletion being associated with a better outcome at 6 and 12 months. Similarly, 
lymphopenia at any time during the course of the patient’s disease course was also associated 
with a better outcome (longer duration of depletion) [30] (Table 3). The quality of evidence 
for the association of the degree or duration of BCD with treatment outcomes or harm was 
graded as very low given imprecision of estimates and limitations of study design. 
With regard to peripheral B cell repopulation, memory and plasmablast cells repopulation at 
26 weeks was significantly associated with earlier relapse and there were also significantly 
higher numbers of memory and plasmablast cells (≥ 0.0008 x 109/liter) in patients with earlier 
relapse in one cohort study (very low QoE) (Table 4). 
In another cohort (very low QoE), higher B-cell numbers could be observed as early as 8 
weeks post-RTX in those with early (before 18 months) relapse. Also, in this study early 
relapse was associated with lower levels of repopulation in patients with high (> 100 UI/ml) 
[27] (Table 4). 
 
4. DISCUSSION 
This systematic review aimed to identify potential predictors of differential treatment effect 
(moderators) in RCTs and prognostic factors from cohort studies for outcomes of RTX 
therapy for SLE. Using validated tools, the overall quality of most of the investigated 
predictive or prognostic factors was low or very low, which means that our confidence in the 
majority of these is very limited. The quality of evidence was affected mainly by limitations 
associated with: (1) the evidence arising generally from explanatory studies conducted in an 
early, hypothesis-generating phase of investigation; (2) risk of publication bias (or small 
study) due to associations of prognostic factors with outcome mainly reported by a very small 
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number of studies with small sample size; (3) several included studies only reported  “p” 
values rather than effect sizes which limits conclusions to be drawn about the precision of 
effect estimates and clinical relevance of the study findings;  (4) results derived from 
subgroup analyses without interaction tests in only  a small number of studies,(5) many 
associations explored in only one study and (6) several studies reported from the same centre 
or cohort, which makes evaluating consistency of results across studies difficult. Even when 
assessing a common marker such as anti-ENA antibodies and B-cell dynamics post-RTX 
different definitions and cut-points between studies limit the ability to validate or confirm 
findings. Further primary hypothesis-driven research based on longitudinal studies of 
sufficient sample size exploring factors associated with RTX outcomes in SLE patients is 
therefore needed to confirm and validate which, if any of these, factors truly predict outcomes 
of RTX therapy. 
 
A number of factors associated with clinical response to rituximab are suggested by this 
review that will require further study. In a pre-specified secondary analysis of the 
EXPLORER trial, African American/Hispanic patients who received RTX were more likely 
to achieve the primary endpoint compared to the same race/ethnicity groups receiving 
standard of care (control arm). This difference was however driven by a lower response to 
standard of care in African American/Hispanic patients compared to overall trial population 
[8]. It therefore remains to be seen whether this simply represents overall less stable disease 
in this subgroup or whether RTX has indeed a differential effect in these race/ethnicity 
subgroups. Similarly in the same trial, RTX treated patients receiving co-therapy with MTX 
achieved a lower global BILAG score by 52 weeks compared to placebo treated patients, 
however the primary endpoint of the trial did not differ according to co-therapy. Whether this 
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represents a particular synergy between RTX and MTX in SLE patients or not, cannot be 
deduced from this data.  
In the cohort studies, the majority of prognostic factors were limited to small early phase 
studies and often a single study examining each factor. Several factors including anti-dsDNA 
status were examined across a number of cohorts [27-29;37] and did not show any 
association with RTX responses (either clinical or serological changes). Any conclusions are 
again limited since most cohorts were small and used different outcomes measures and also 
there have been a number of cohorts from which multiple publications have arisen and it is 
unclear the degree of overlap in the patients studied. We therefore cannot confidently exclude 
such a factor as being of importance.  
A number of factors suggested in at least one study included IL2/IL21 SNP GG genotype and 
G allele which were associated with global clinical response in one cohort study [36]. Whilst 
this needs confirmation in a much larger cohort, attention also needs to be paid to whether it 
is a predictor of response only for RTX or whether it simply predicts a better response to 
other immune-modulatory therapy as well. This will be important to determine the true 
significance of such a predictive biomarker. Of interest in a recent systematic review of 
predictors of response to biologic therapy in RA, conflicting results were reported for FCGR 
variants and no association between RTX responses and IL6 promoter 174 were observed 
[38]. In SLE these variants also did not show any association with global SLE responses to 
RTX.   
Two single-centre cohort studies found that the level of B cell depletion achieved as well as 
the early return of B cell (especially plasmablasts and memory B cells) were associated with 
early relapses in studies from two cohorts [13;27]. Such factors are of interest as the latter 
pattern of B-cell depletion and return are likely to be specific to the action of RTX and 
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therefore will act as a pharmacodynamic measure of RTX efficacy and future relapses. At a 
pragmatic and clinical level, more complex monitoring than simply assessing baseline factors 
may therefore be needed to fully understand the specificity of responses to RTX and to plan 
more tailored therapy. Such dynamic markers of course have the limitation of not allowing 
clinicians to decide a priori whether to treat or not treat with RTX but will be of great value 
in planning future courses and potentially helping to make an early declaration of therapeutic 
‘failure’ so that other therapies can be initiated sooner. For such factors to be validated to the 
degree of certainty required to formalise therapeutic decisions will however require large 
multicentre, quality assured confirmatory studies. Such studies do also provide potentially 
important insights into the mechanisms of action of RTX in mediating prolonged responses in 
some patients. Recent work on regulatory B cells suggests that it is likely to be the pattern of 
return of B-cell subsets rather that total B-cell numbers that determine future relapses, 
providing a potential explanation for the inconsistencies in the value of B cell markers in 
determining response in the cohorts reviewed [39].  
We noted that there are differences across studies in how specific organ systems responded to 
RTX therapy. For example, one small study suggested that Ro+ve patients and those with 
chronic cutaneous lupus had poorer responses [37]. In addition patients with elevated 
creatinine and those with longer duration of LN responded less well in one cohort study [28]. 
Whether these observations relate to more scarring/fibrosis and hence a lower likelihood of 
response in these subsets or whether they point to a different pathogenesis (e.g. T-cell or IFN-
driven disease) will require further study. All these studies were however rated as low or very 
low QoE and therefore confirmation of these observations are necessary in parallel with a 
better understanding of the explanations for any such lack of response to RTX.  
Factors related with drug administration such as concomitant therapy, administration 
schedules or human antichimeric antibodies (HACA) were not included in our analysis as 
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such studies are more focused on optimal delivery of the treatment, rather than investigating 
which patient or disease characteristics (prognostic factors) are associated with positive 
outcomes of treatment.   
The strength of this review lies in the fact that this is the first comprehensive review that 
provides a summary of the possible predictive or prognostic factors in SLE patients with 
RTX therapy. However, we recognise several limitations to the review. First, due to the small 
number of studies included and the heterogeneity between studies we were not able to 
combine the results of studies from a quantitative perspective. We have also synthesized the 
evidence on associations between a single potential prognostic factor and an outcome 
variable when the study employed either univariable analyses or multivariable analyses. By 
including both types of analyses we may have introduced a degree of heterogeneity.   One 
major limitation is that even in these best case scenarios, the variables controlled for in each 
analysis may differ between studies and we therefore cannot assume that any of the single 
identified associations would remain if more consistent modelling was applied in all studies. 
Second, most studies included in this systematic review were in SLE patients who failed to 
respond to conventional treatment, therefore, we cannot extrapolate our results to patients 
with newly diagnosed SLE, who are candidate for standard therapy. A few small studies have 
assessed the effectiveness of rituximab in those patients [40;41], however, some of these 
studies were not included in our review due to mainly either no prognostic factor analysis 
was provided or less than 30 patients were included (Supplementary file A, Table A.7).  
Third, It is also possible that we have missed studies that are not indexed in these databases, 
but by checking references of included studies, we made every effort to identify all relevant 
articles.  Finally, no attempt was made to contact authors to obtain individual patient-level 
data or carry out a comprehensive meta-analysis. 
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Clinical experience, observational studies and several international guidelines [10;11] support 
the use of RTX for the treatment of refractory SLE as well as disease with sustained activity 
that persists despite conventional immunosuppression therapy. Despite of more widespread 
use and studies supporting its efficacy, we found limited evidence to predict which patient 
groups will respond better (or worse) to RTX to permit a stratified approach to the use of this 
agent. A number of demographic, serological, genetic and pharmacodynamic markers were 
identified in this review, however most studies addressing these prognostic factors were 
hypothesis-generating and therefore cannot be used to make any specific recommendations 
for routine clinical practice. It is therefore important to validate any predictive or prognostic 
factors in hypothesis-testing studies and determine whether such markers are associated with 
SLE outcomes in general or whether they are specific for RTX therapy. Such an approach 
will   pave the way for more personalised use of this agent in the future. 
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